Last checked at 14 Feb 2019 07:00
Renalytix AI plc
("RenalytixAI" or the "Company")
Appointment of Nomad and Joint Broker
Further to the announcement on 20 December 2018, Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the appointment of Stifel as the Company's nominated adviser and joint broker with immediate effect. N+1 Singer will continue to act as joint broker.
For further information, please contact:
Renalytix AI plc | www.renalytixai.com | ||
James McCullough, CEO | Via Walbrook PR
| ||
|
| ||
Stifel (Nominated Adviser & Joint Broker) | Tel: 020 7710 7600 | ||
Alex Price / Jonathan Senior / Ben Maddison (Investment Banking) Peter Lees (Corporate Broking) |
| ||
|
| ||
N+1 Singer (Joint Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / James White / George Tzimas (Corporate Finance)Tom Salvesen / Mia Gardner (Corporate Broking) |
| ||
|
| ||
|
| ||
|
| ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | ||
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant and an estimated $114 billion is spent annually treating chronic kidney disease in the US.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.